Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:17 AM
Ignite Modification Date:
2025-12-25 @ 12:17 AM
NCT ID:
NCT04927858
Eligibility Criteria:
Inclusion criteria
Population 1: 'Prevalence of a history of cardiovascular disease (CVD) among persons with type 2 diabetes mellitus (T2DM) who were alive on 31 December 2017' :
* Diagnosed with T2DM in Sweden
* Alive on 31 December 2017
* At least one registration in the Swedish National Diabetes Register (NDR)
* Each patient provides informed consent for inclusion in the register
Population 2: 'Prevalence of a history of CVD among persons with type 2 diabetes who started empagliflozin treatment between 1 January 2015 and 31 December 2017':
* Diagnosed with T2DM in Sweden
* Alive on 31 December 2017
* Initiated on empagliflozin between 1 January 2015 and 31 December 2017
* At least one registration in the NDR
* Each patient provides informed consent for inclusion in the register
Exclusion criteria:
none
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT04927858
Study Brief:
Protocol Section:
NCT04927858